A biosimilar is a biologic drug that's highly similar to an existing FDA-approved reference product, with no clinically meaningful differences in safety or effectiveness. Biosimilars typically become available after a reference drug's patent protections expire, potentially offering lower-cost alternatives — relevant to GLP-1 medications as patents on early drugs in this class begin to expire in coming years.